Dr Eric Bouffet presents study findings, where he found two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in paediatric patients with BRAF V600 mutation-positive low-grade gliomas.

The next steps for this study are that researchers hope to learn more about the optimal duration of treatment.

Also, the researchers hope to determine if this treatment fits into the World Health Organisation (WHO) global initiative for childhood cancer.

Read the news story here

Watch Dr Hudson comment on the study here

Watch Dr Bouffet's interview on the study here